Expertise in
27
conditions

Dr. Jeffrey D. Bradley

Radiation Oncology
3400 Civic Center Boulevard, Concourse Level, 
Philadelphia, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
27
conditions
3400 Civic Center Boulevard, Concourse Level, 
Philadelphia, PA 

Overview

Jeffrey Bradley is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Bradley is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

Dr. Bradley is board certified in Radiation Oncology, 1998. He is actively involved in clinical research, co-authoring 226 peer reviewed articles and participating in 9 clinical trials. Dr. Bradley is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in MO

Board Certifications

Radiation Oncology, 1998

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Penn Presbyterian Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 10 Less Insurance Carriers -

Locations

Penn Radiation Oncology Perelman-Concourse Level
3400 Civic Center Boulevard, Concourse Level, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Bradley has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Other, Drug, Biological, Radiation
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 21, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: 18F-Fluoromisonidazole, Carboplatin, Fludeoxyglucose F-18, Paclitaxel
Study Phase: Phase 2
A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer
A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Radiation, Other
Study Phase: Not Applicable
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug, Device, Biological, Radiation
Study Drugs: Paclitaxel, Carboplatin AUC, Durvalumab
Study Phase: Phase 2
A Virtual Clinical Trial to Assess the Impact of Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy
A Virtual Clinical Trial to Assess the Impact of Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy
Enrollment Status: Terminated
Publish Date: March 01, 2024
Intervention Type: Device
Study Phase: Not Applicable
Registry for Proton Beam Radiation Therapy
Registry for Proton Beam Radiation Therapy
Enrollment Status: Completed
Publish Date: July 24, 2023
Objective Treatment Allocation With SBRT vs. Surgery in High Risk Patients With Early Stage Lung Cancer Within an Accountable Care Collaborative Effort Between Surgery and Radiation Oncology
Objective Treatment Allocation With SBRT vs. Surgery in High Risk Patients With Early Stage Lung Cancer Within an Accountable Care Collaborative Effort Between Surgery and Radiation Oncology
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT) Dose Escalation in the Treatment of Patients With Inoperable Stage I/II Non-Small Cell Lung Cancer Arising Within the Zone of the Proximal Bronchial Tree
A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT) Dose Escalation in the Treatment of Patients With Inoperable Stage I/II Non-Small Cell Lung Cancer Arising Within the Zone of the Proximal Bronchial Tree
Enrollment Status: Completed
Publish Date: July 30, 2019
Intervention Type: Radiation
Study Phase: Phase 1/Phase 2
Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)
Phase I/II Trial of Lithium as a Neuroprotective Agent for Patients With Small Cell Lung Cancer (SCLC) Treated With Prophylactic Cranial Irradiation (PCI)
Enrollment Status: Completed
Publish Date: July 05, 2018
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

226 Total Publications

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Journal: Lancet (London, England)
Published: June 27, 2026
Similar Doctors
Expertise in
38
conditions
Dr. Keith A. Cengel
Radiation Oncology
Expertise in
38
conditions
Dr. Keith A. Cengel
Radiation Oncology
Referral may be required
Before you request

Penn Radiation Oncology Perelman - 2nd Floor

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Cengel is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cengel is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Mesothelioma, Lung Cancer, Metastatic Pleural Tumor, Small Cell Lung Cancer (SCLC), and Liver Embolization. Dr. Cengel is board certified in Radiation Oncology, 2008. Dr. Cengel is currently accepting new patients.

Expertise in
34
conditions
Dr. Wenyin J. Shi
Radiation Oncology
Expertise in
34
conditions
Dr. Wenyin J. Shi
Radiation Oncology
Referral may be required

Radiation Oncology At Thomas Jefferson University Hospital

111 South 11th Street, Suite G-301, 
Philadelphia, PA 
 (1.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wenyin Shi is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Shi is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Mycosis Fungoides, Glioblastoma, Brain Tumor, and Gamma Knife Radiosurgery. Dr. Shi is board certified in Radiation Oncology and Radiology. Dr. Shi is currently accepting new patients.

Expertise in
30
conditions
Dr. Maria Werner-Wasik
Radiation Oncology
Expertise in
30
conditions
Dr. Maria Werner-Wasik
Radiation Oncology
Referral may be required

1100 Walnut St

1100 Walnut St, 
Philadelphia, PA 
 (1.8 miles away)
800-533-3669
Languages Spoken:
English
See accepted insurances

Maria Werner-Wasik is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Werner-Wasik is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Astrocytoma, Glioblastoma, Schwannoma, and Lung Cancer.

Frequently Asked Questions about Dr. Jeffrey D. Bradley

How do I make an appointment with Dr. Jeffrey D. Bradley?

You can book an appointment with Dr. Jeffrey D. Bradley by calling their office at 800-789-7366. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey D. Bradley a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey D. Bradley is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey D. Bradley specialize in?

While Dr. Jeffrey D. Bradley is a Radiation Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Jeffrey D. Bradley participate in research or clinical trials?

Yes. Dr. Jeffrey D. Bradley has published 226 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Jeffrey D. Bradley's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey D. Bradley accept my insurance?

Dr. Jeffrey D. Bradley accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 800-789-7366 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bradley's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile